Subarachnoid Hemorrhage Clinical Trials

Find Subarachnoid Hemorrhage Clinical Trials Near You

Prospective Monocentric Study Comparing Cerebral Perfusion Parameters From an ULtrasonic Imaging System With Measures Provided by Clinical Routine Perfusion CT

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The primary goal of neurocritical care is to prevent secondary brain injury, which worsens neurological outcomes. Because clinical monitoring is often insufficient due to the patient's condition and medical treatments, multimodal monitoring using biophysical, electrophysiological, and imaging data is essential. In patients with subarachnoid hemorrhage (SAH), the most frequent and severe complication is delayed cerebral ischemia, often linked to arterial vasospasm and potentially leading to infarction. Early diagnosis combines transcranial Doppler (TCD), sensitive to vasospasm, with perfusion CT (CTP), which measures cerebral perfusion; this approach guides therapy and improves prognosis. Ultrasound, especially when enhanced with contrast agents (CEUS), allows non-invasive, bedside, repeated visualization of cerebral blood flow and perfusion-even through the skull. Agents like SonoVue® help quantify perfusion using time-intensity curves. The study aims to assess whether cerebral perfusion measurements from the SYLVER device are equivalent to those from CTP in ICU or CCU patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient ≥ 18 years old

• Patient Informed Consent, or from his/her relative if the patient is not conscious and able to consent

• Admission to ICU or CCU with indication to perform at least one CTP

• Affiliated with or benefiting from a social security scheme

• The subject's current clinical status, as assessed by medical history, physical examination, and/or relevant tests, indicates that they do not require immediate medical treatment or emergency care at the time of enrolment.

Locations
Other Locations
France
Centre Hospitalo-Universitaire Gui de Chauliac
RECRUITING
Montpellier
Contact Information
Primary
Vivien Szabo, MD, PHD
v-szabo@chu-montpellier.fr
+33467336733
Time Frame
Start Date: 2025-10-25
Estimated Completion Date: 2026-08-15
Participants
Target number of participants: 50
Treatments
Experimental: Patients admitted to the ICU or CCU
Indication for at least one CTP to assess the risk of cerebral hypoperfusion.
Related Therapeutic Areas
Sponsors
Leads: Resolve Stroke

This content was sourced from clinicaltrials.gov